Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Bio Pharma Dive
OCTOBER 25, 2024
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.
Twist Bioscience and Astellas team up for antibody discovery
Pharmaceutical Technology
APRIL 21, 2023
Twist Bioscience and Astellas Pharma have entered a collaboration to help the latter to discover antibodies for immunotherapies. In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression.
Antibody 
264
264 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lilly reports fast sales for new diabetes drug
Bio Pharma Dive
FEBRUARY 2, 2023
Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.
Sales 164
164 
JPM21: Vaccines soar, antibodies struggle as COVID-19 drugs become a business
Bio Pharma Dive
JANUARY 12, 2021
Moderna and Gilead reported billions in sales for their coronavirus treatments, but Regeneron's antibody drug cocktail hasn't gained traction. BioNTech, meanwhile, could report critical new vaccine results in days.
Antibody 301
301 
Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is a monoclonal antibody that targets amyloid beta A4 protein and acts by selectively binding and eliminating amyloid beta plaques, thought to be clinically significant for the treatment of Alzheimer’s disease.
Sales 147
147 
GSK beats forecasts, thanks to COVID antibody and Shingrix sales
pharmaphorum
APRIL 27, 2022
GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding £1.3 billion with no sales recorded in the prior year.
Sales 97
97 
Brii Bio acquires Vir’s antibody rights for Hepatitis B in Greater China
Pharmaceutical Technology
JULY 4, 2022
Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.
Antibody 279
279 
Alzheimer’s drug Leqembi set to generate $12.9bn in sales by 2028
Pharmaceutical Technology
MARCH 30, 2023
The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is a monoclonal antibody that targets amyloid beta A4 protein and acts by selectively binding and eliminating amyloid beta plaques, thought to be clinically significant for the treatment of Alzheimer’s disease.
Sales 130
130 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. MGD024 is an investigational bispecific antibody that attaches to CD123 and CD3. The post Gilead partners with MacroGenics for bispecific antibody development appeared first on Pharmaceutical Technology.
Antibody 130
130 
Twist and Ildong to develop antibodies for immuno-oncology applications
Pharmaceutical Technology
JULY 1, 2022
Ildong Pharmaceutical will licence a suite of Twist Bioscience's VHH antibody libraries after the two companies entered a partnership agreement. Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. .
Antibody 147
147 
Antibody aficionado Abcam explores strategic alternatives—including a potential sale
Fierce Pharma
JUNE 29, 2023
Half a decade after Abcam quit its 270 million pound sterling pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the opposite end of the dealmaking t | Half a decade after Abcam quit its £270 million pursuit of Horizon Discovery, the British antibody research expert has potentially found itself on the (..)
Antibody 94
94 
Biocytogen and ADC to evaluate antibodies for three cancer targets
Pharmaceutical Technology
NOVEMBER 27, 2022
Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.
Antibody 130
130 
Daiichi Sankyo again dials up Enhertu sales forecast, advances 2nd AstraZeneca-partnered ADC
Fierce Pharma
JANUARY 31, 2024
AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.<
Sales 100
100 
ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale
Fierce Pharma
MAY 6, 2024
In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ADC Therapeutics provided several company updates Monday, including that it's raising $105 million through a sale of common shares and pre-funded (..)
Sales 106
106 
Scholar Rock preps filings after SMA antibody clears trial
pharmaphorum
OCTOBER 8, 2024
billion, as analysts started to talk about a blockbuster sales opportunity for the selective myostatin inhibitor. Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings in early 2025.The
Antibody 111
111 
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.
Antibody 130
130 
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
Fierce Pharma
OCTOBER 25, 2024
homing in on approval for its infant respiratory syncytial virus antibody clesrovimab, Sanofi thinks Beyfortus can hold its own. Despite Merck & Co. Despite Merck & Co. On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more competition in the space is a net positive.
Sales 113
113 
After Catalent rumors, Danaher strikes $5.7B deal to acquire antibody specialist Abcam
Fierce Pharma
AUGUST 28, 2023
It’s a sale. Two months after Abcam launched a strategic review of the company, the British antibody research expert has revealed that it’s being bought by Danaher. Danaher Corporation is picking up all outstanding shares of Abcam for $24 apiece. Both companies’ boards unanimously approved the decision, Danaher and Abcam said Monday.
Antibody 98
98 
Intas licenses Helnius’s antibody for marketing in Europe and India
Pharmaceutical Technology
OCTOBER 30, 2023
Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.
Licensing 147
147 
XBiotech Announces Receipt of $75 Million from Sale of Antibody
BioTech 365
JUNE 30, 2021
XBiotech Announces Receipt of $75 Million from Sale of Antibody XBiotech Announces Receipt of $75 Million from Sale of Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody AUSTIN, Texas, June 30, … Continue reading →
Sales 40
40 
One dose of Regeneron’s COVID antibody protects for eight months
pharmaphorum
NOVEMBER 8, 2021
A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on. That was down from almost $2.6
Antibody 105
105 
Regeneron tries to shake off fall in COVID drug sales with first quarter earnings
Bio Pharma Dive
MAY 4, 2022
revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread. Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S.
Sales 154
154 
Rebranded Servier eyes €3bn in cancer drug sales by 2030
pharmaphorum
OCTOBER 6, 2022
Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen. billion and $1.8 billion, rising to €8 billion and approximately €2.4
Sales 98
98 
AbbVie begins trials of COVID-19 antibody therapy
pharmaphorum
DECEMBER 16, 2020
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.
Antibody 98
98 
Merck Touts Strong Growth in Keytruda Sales, ADC Business in Q3
BioSpace
OCTOBER 26, 2023
billion in the third quarter, a 17% increase from the same period last year, while bolstering its antibody-drug conjugate portfolio. The company’s blockbuster cancer asset Keytruda brought in more than $6.3
Sales 104
104 
Antibody Drug Conjugates Market Update: Ambrx and NovoCodex Collaborate
Roots Analysis
FEBRUARY 27, 2024
Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period. Check the details of the agreement here.
Antibody 40
40 
Top 20 Drugs in 2023 by 2022 Sales Statistics
XTalks
DECEMBER 19, 2023
As we approach the end of 2023, a retrospective look at the statistics from 2022 reveals the top 20 drugs dominating retail sales. In this article, we will explore the factors contributing to the success of the top 20 drugs in 2023 by retail sales from the prior year. 1) Comirnaty (COVID-19 Vaccine, mRNA) Sales in 2022: $37.81
Sales 64
64 
Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld
pharmaphorum
AUGUST 12, 2022
Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. One group of Chinese researchers has reported however that BA.4
Antibody 145
145 
AZ, Sanofi get first green light for RSV prophylactic antibody
pharmaphorum
NOVEMBER 6, 2022
The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement.
Antibody 64
64 
GSK gets £1.4bn sales lift from COVID-19 products in 2021
pharmaphorum
FEBRUARY 9, 2022
GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6 billion but have been.
Sales 105
105 
With capacity upgrades ready to roll, Sanofi stands firm on blockbuster sales goal for RSV drug in 2024
Fierce Pharma
JULY 25, 2024
While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus (RSV) drug, the near-term expected approval of a pair of new filling lines is giving the | While manufacturing and supply hitches have troubled the rollout of Sanofi’s key respiratory syncytial virus drug, the near-term expected approval of (..)
Sales 108
108 
Pfizer’s COVID boom goes on, as it eyes $22bn in Paxlovid sales this year
pharmaphorum
FEBRUARY 8, 2022
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty. Pfizer shares actually fell in the wake of its results announcement as some analysts had been forecasting higher sales for Comirnaty this year.
Sales 98
98 
Strike two for Novartis’ lung cancer antibody canakinumab
pharmaphorum
OCTOBER 25, 2021
Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.
Antibody 124
124 
Moderna COVID-19 jab sales rocket to $4.2 billion in second quarter
pharmaphorum
AUGUST 6, 2021
billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. Moderna is now predicting sales of $20 billion for 2021 as a whole from up to 1 billion doses delivered, which compares to Pfizer estimate of $33.5 Moderna made a massive $4.2
Sales 105
105 
Fierce Pharma Asia—Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale
Fierce Pharma
AUGUST 29, 2024
BioNTech's antibody-drug conjugate partner, DualityBio, has filed for a Hong Kong IPO. Sanofi has suspended distribution of its two flu vaccines in China out of concern of waning potency. Sanofi has suspended distribution of its two flu vaccines in China. BioNTech's ADC partner, DualityBio, has filed for a Hong Kong IPO.
Sales 79
79 
Eli Lilly’s COVID-19 Monoclonal Antibodies Cleared to Battle Delta
XTalks
SEPTEMBER 7, 2021
After a two-month long halt, federal officials have given the go-ahead to resume nationwide distribution of Eli Lilly’s COVID-19 monoclonal antibodies bamlanivimab and etesevimab. However, studies now show the COVID-19 monoclonal antibodies can work against the variant. 1 and Beta/B.1.351, 1.351, respectively). “The
Antibody 93
93 
Roche Q3 results show steep fall-off in COVID product sales
pharmaphorum
OCTOBER 18, 2022
Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off. COVID-19 diagnostic sales fell from CHF 1 billion ($1.01 billion of its total pharma sales of CHF 33.19
Sales 52
52 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.
Research 130
130 
After withdrawal, GSK touts another Blenrep combo win as analysts build blockbuster case for the myeloma ADC
Fierce Pharma
MARCH 7, 2024
GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.
Antibody 114
114 
US companies drive 2023 drug launches positioned for blockbuster success by 2028
Pharmaceutical Technology
MAY 30, 2023
Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda.
Drugs 264
264 
Merck Enters into a Development Agreement with Daiichi for Antibody Drug Conjugates
Roots Analysis
OCTOBER 25, 2023
On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. According to Roots Analysis, the antibody drug conjugate market is estimated to be worth $7.72
Antibody 40
40 
Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody
pharmaphorum
OCTOBER 18, 2022
Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Along with the signing fee, there is another $1.7 It brought in $4.7
Antibody 52
52 
AZ, Sanofi build case for one-shot RSV antibody
pharmaphorum
MAY 11, 2022
A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respiratory tract infections caused by the pathogen. versus placebo. versus placebo.
Antibody 64
64 
Regeneron reports 7 per cent rise in Q1 2023 total revenue
Pharmaceutical Technology
MAY 5, 2023
In the US, Eylea’s (aflibercept) net product sales decreased by 6% to $1.43bn from $1.5bn in Q1 2022 owing to a rise in sales-related deductions, partly offset by higher sales volume. Worldwide net sales of Dupixent increased by 37% to $2.49bn Q1 to Q1 2022-23. “We
Sales 130
130 
Let's personalize your content